H.C. Wainwright Reiterates Buy Rating on Intensity Therapeutics, Inc. (INTS)
The analyst maintains a bullish stance with a higher target, suggesting upside potential for INTS.
Public signal · 1-minute delayed
Source-backed market context you can read and share without an account.
The analyst maintains a bullish stance with a higher target, suggesting upside potential for INTS.
What happened, with direct paths to the underlying reporting
Analyst reiterates Buy with a higher implied path to a $7 target, signaling upside from the current price around $4.21.
Target: $7
Posted price: $4.21
Analyst firm: H.C. Wainwright
Analyst: Swayampakula Ramakanth
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.